Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 23, 2019. The report covers events occurring on that date, specifically the issuance of a new patent by the U.S. Patent and Trademark Office.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance.
Material Changes
On January 23, 2019, the company received U.S. Patent No. 10,155,006, entitled "Combination Therapies and Methods of Use Thereof for Treating Cancer." This represents an expansion of the company's intellectual property portfolio.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. The document solely announces the patent grant.
Investor Verification Checklist
- Verify the exact scope and claims of U.S. Patent No. 10,155,006.
- Confirm the company's current name is Trovagene, Inc., as the input metadata referenced Cardiff Oncology, Inc.
- Review the attached press release (Exhibit 99.1) for details on how this patent impacts the company's product pipeline.